Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
SUPERa Stenting After SUBintimal Crossing of TASC C-D Femoro-popliteal Lesions in CLI Patients
NCT03452293 · View on ClinicalTrials.gov ↗
Study Summary
The study will evaluate the safety and efficacy of subintimal Supera stenting in complex de novo or re-occlusive CTO (TASC C-D) lesions in patients with CLI. This study will be performed based on a rigorous sample size calculation, which will allow us to have the statistical power to validate our conclusions and therefore establish the generalizability of this strategy.
Conditions Studied
Interventions
- DEVICE Stent Peripheral System
Study Locations (15)
RM
- Policlinico Tor Vergata — Roma
- A.O. San Giovanni Addolorata — Roma
Michigan
- Metro Health Hospital — Wyoming
Santa Fe Province
- Instituto Medico CENICLAR, Unidad Sanatorio de la Mujer — Rosario
AQ
- Ospedale di Avezzano — Avezzano
CE
- Clinica San Michele — Maddaloni
CT
- A.O.U. Policlinico Vittorio Emanuele — Catania
LE
- A.O. Cardinale Panico — Tricase
Padova
- Casa di Cura Abano Terme — Abano Terme
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2018-03-07 |
| Est. Completion | 2022-03-28 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03452293
The ClinicalTrials.gov registry entry for NCT03452293 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EndoCore Lab s.r.l., which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with PAD appearing as the primary indexed condition, and to 1 intervention — of which Stent Peripheral System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03452293 reports 15 study locations spanning 14 distinct geographic areas — top geographies include RM, Michigan, Santa Fe Province. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03452293 about?
NCT03452293 is a clinical study titled "SUPERa Stenting After SUBintimal Crossing of TASC C-D Femoro-popliteal Lesions in CLI Patients". The study will evaluate the safety and efficacy of subintimal Supera stenting in complex de novo or re-occlusive CTO (TASC C-D) lesions in patients with CLI. This study will be performed based on a rigorous sample size calculation, which will allow us to have the statistical power to validate our co...
What is the current status of trial NCT03452293?
This trial is currently completed. The enrollment target is 92 participants. The study started on 2018-03-07. Estimated completion is 2022-03-28.
What conditions does trial NCT03452293 study?
This clinical trial studies the following conditions: PAD. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03452293?
The interventions under investigation include: Stent Peripheral System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03452293?
This trial is sponsored by EndoCore Lab s.r.l., which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03452293 being conducted?
This trial has 15 study locations across Michigan, Santa Fe Province, AQ, CE, CT. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.